887 thousand new cases of cervical cancer registered worldwide in 2023

The use of drugs intended for weight reduction, known as GLP-1s, has gained increasing popularity in recent years. The beauty sector giant, L'Oréal, stated that this increase in medication consumption has negatively impacted the sales of beauty and skincare items.

In response to this trend, the company is investing in the development of new products focused on mitigating certain adverse effects resulting from rapid weight loss.

Nicolas Hieronimus, the company's CEO, assured that despite the globally challenging scenario, the beauty market has proven resilient. He described the use of GLP-1s as 'a very important phenomenon for us.' In dialogue with investors, Hieronimus detailed that the growth in the use of these medicines was generating an impact on the consumption of beauty products, especially skincare articles.

L'Oréal, which owns recognized brands such as Maybelline and La Roche-Posay, announced on Thursday, the 22nd, that its sales registered a 7.7% advance in the three months ending in September, surpassing analysts' projections.

The rise in the popularity of GLP-1s occurred after medications initially created for diabetes treatment, such as Ozempic, Wegovy, and Mounjaro, also demonstrated the ability to induce considerable weight loss through appetite suppression.

Although skin laxity is not a direct effect of the GLP-1 medications themselves, rapid weight loss can cause this condition in some people, including in the facial area.

Hieronimus mentioned that the brands SkinCeuticals and Kiehl's, both belonging to L'Oréal, have products designed to work synergistically with GLP-1s, complementing their effects in combating skin laxity and other issues related to rapid weight loss.

Additionally, L'Oréal expanded its presence in the field of clinical aesthetics, raising its stake in the dermatology company Galderma to 20% in December of the previous year.

According to the Reuters agency, the two corporations are conducting product tests in separate clinical trials involving GLP-1 users who are concerned about facial laxity. Galderma markets notable aesthetic products, such as Sculptra, an injectable used to stimulate collagen production, and Restylane, an injectable dermal filler.

Last year, the aesthetics company published a report addressing the increased use of GLP-1s and concerns related to changes in facial appearance. A survey conducted by the company itself among those using weight loss medications revealed that most had noticed changes in their facial appearance after using these treatments.

Couples are increasingly resorting to IVF to fulfill their dream of parenthood. According to a report by Evendus, approximately 320 thousand IVF cycles were conducted in the country by June 2024, but this figure could rise to 550 thousand by 2028. Furthermore, the increase in people seeking IVF is viewed as a sign of deteriorating overall health.

IVF centers in various hospitals note that fertility problems affect not only women but also men in significant numbers.

Dr. Mega Mittal, senior consultant at Apollo Spectra Hospital in Delhi, notes that in 2023, approximately 200–250 thousand IVF cycles were performed annually, and this figure could reach 500–600 thousand by 2030. The number of couples seeking treatment and the total number of IVF cycles are increasing over time.

Dr. Nidhi Sehrawat from Christa IVF reported a substantial rise in interest in IVF: consultations for IVF increased by 33.2% in 2025–2026, and the IVF cycles themselves increased by 58.6%. Additionally, the number of patients rose by 40.1%.

According to Dr. Nidhi, about 35 percent of women visiting her center for IVF suffer from Polycystic Ovary Syndrome (PCOS) and use IVF as a treatment method. She also emphasized that in about half of cases, there are fertility problems in men, including reduced sperm count and poor sperm quality.

Dr. Nidhi specified that reduced sperm count is called oligozoospermia, and this problem has become more common among men in recent years. Dr. Mega also observed that these two conditions are often found in couples undergoing IVF. She noted that fertility is impaired not only in women but also in men, affecting 20–30% of men. Major causes cited include poor nutrition, late marriage, age, and women's decision to postpone starting a family.

At Atlantis Healthcare, gynecologist Dr. Mannan Gupta explained that the growing demand for IVF is due to both lifestyle and medical reasons. These include later marriage and the decision to start a family at an older age. In women, egg cell quantity decreases with age, and many cannot conceive naturally due to PCOS. Similarly, in men, sperm count decreases with age.

A consultation with a doctor is necessary if pregnancy does not occur after attempts at natural conception for one year. Generally, women under 35 are recommended to undergo examination after one year of attempts, while women aged 35 and older should be examined after six months. It is also advised to consult a specialist if a woman has been diagnosed with PCOS, or if a man feels discomfort related to his health.